1. The Phenotypic Effects of Exosomes Secreted from Distinct Cellular Sources: a Comparative Study Based on miRNA Composition.
- Author
-
Ferguson S, Kim S, Lee C, Deci M, and Nguyen J
- Subjects
- Animals, Cadherins metabolism, Computational Biology, Gene Expression Profiling, HEK293 Cells cytology, HEK293 Cells metabolism, Humans, Integrin beta3 metabolism, MCF-7 Cells cytology, MCF-7 Cells metabolism, Mice, PC-3 Cells cytology, PC-3 Cells metabolism, Phenotype, RAW 264.7 Cells cytology, RAW 264.7 Cells metabolism, Signal Transduction, Drug Delivery Systems methods, Exosomes metabolism, MicroRNAs metabolism
- Abstract
Exosomes are nano-sized vesicles composed of lipids, proteins, and nucleic acids. Their molecular landscape is diverse, and exosomes derived from different cell types have distinct biological activities. Since exosomes are now being utilized as delivery vehicles for exogenous therapeutic cargoes, their intrinsic properties and biological effects must be understood. We performed miRNA profiling and found substantial differences in the miRNA landscape of prostate cancer (PC3) and human embryonic kidney (HEK) 293 exosomes with little correlation in abundance of common miRNAs (R
2 = 0.16). Using a systems-level bioinformatics approach, the most abundant miRNAs in PC3 exosomes but not HEK exosomes were predicted to significantly modulate integrin signaling, with integrin-β3 loss inducing macrophage M2 polarization. PC3 but not HEK exosomes downregulated integrin-β3 expression levels by 70%. There was a dose-dependent polarization of RAW 264.7 macrophages toward an M2 phenotype when treated with PC3-derived exosomes but not HEK-derived exosomes. Conversely, HEK exosomes, widely utilized as delivery vehicles, were predicted to target cadherin signaling, with experimental validation showing a significant increase in the migratory potential of MCF7 breast cancer cells treated with HEK exosomes. Even widely utilized exosomes are unlikely to be inert, and their intrinsic activity ought to be assessed before therapeutic deployment.- Published
- 2018
- Full Text
- View/download PDF